tbuckley/cabot-search huggingface dataset:
A Yeast Estrogen Screen for Examining the Relative Exposure of Cells to Natural and Xenoestrogens
Authors: Steven F. Arnold, Matthew K. Robinson, Angelo C. Notides, Louis J. Guillette, John A. McLachlan
Journal: Environmental Health Perspectives (1996)

Xenoestrogens, such as o,p'-DDT and octyl phenol (OP), have been associated with reproductive abnormalities in various wildlife species. Xenoestrogens mimic the natural estrogen 17 beta-estradiol and compete for binding to the estrogen receptor. Even though the affinity of o,p'-DDT and OP for the estrogen receptor is approximately 1000-fold lower than 17 beta-estradiol, the actions of xenoestrogens could be enhanced if their bioavailability in serum were greater than 17 beta-estradiol. To test this hypothesis, the yeast estrogen screen (YES) was created by expressing human estrogen receptor (hER) and two estrogen response elements (ERE) linked to the lacZ gene. The beta-galactosidase activity of the YES system was significantly increased after treatment with 17 beta-estradiol or the xenoestrogens diethylstilbestrol (DES), o,p'-DDT, and OP but not with vehicle, antiestrogen ICI 164,384, dexamethasone, or testosterone. To determine whether serum proteins affected the bioavailability of natural estrogens compared to xenoestrogens, albumin, sex hormone binding globulin (SHBG), or charcoal-stripped serum were added to the YES system and beta-galactosidase activity assayed. Albumin and SHBG decreased beta-galactosidase activity in the presence of estradiol to a greater extent than DES, o,p'-DDT, and OP. Human and alligator charcoal-stripped serum were also effective at selectively reducing beta-galactosidase activity in the presence of estradiol compared to xenoestrogens. Human serum was more effective than alligator serum in reducing beta-galactosidase activity in the presence of xenoestrogens, indicating that serum may serve as a biomarker for sensitivity to xenoestrogens. Selective binding of 17 beta-estradiol by proteins in serum indicates that certain xenoestrogens may exert greater estrogenicity than originally predicted. The estrogenic potency of a compound involves its binding affinity, bioavailability in serum, and persistence in the environment. Our data demonstrate the utility of the YES system for identifying and characterizing environmental estrogens.
Atypical measles in adolescent siblings 16 years after killed measles virus vaccine
Authors: V. A. Fulginiti
Journal: JAMA (1980)

The history of killed and live measles vaccine administration and exposure to natural disease is detailed in four adolescent siblings over a 16-year period. In two of these siblings, atypical measles developed 16 years after killed measles virus vaccine was administered, despite intercurrent doses of live measles virus vaccine. (<i>JAMA</i>244:804-806, 1980)
The Willies
Authors: Paula Tatarunis
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the American Orthopedic Association, Ninth Session, held at Chicago, Sept. 17-19, 1895
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multiple Renal Tubular Defects
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute Otitis Media.
Authors: J. O. Malsbury
Journal: JAMA (1897)

Peru, Ind., March 8, 1897. <h3>To the Editor:</h3> —In the case of acute otitis media in the person of Dr. Merrill Hopkinson of Baltimore, and reported by him in the February 27 number of ourJournal, the course of his ailment, infection of the middle ear by the product of a mild attack of post-nasal catarrh, after using a nasal douche, by forcibly blowing the nose, and his treatment as outlined by him does not occur to me to harmonize very well, even though he considered that his treatment obtained good results. In the first place, if his ear was infected as he states, and by the product he mentions, the indications would have been to use a Eustachian catheter in connection with an air-bag, and have blown out the offending substance, instead of continuing to jeopardize his sound ear as well as the crippled one by holding the nose
Annales D'Oculistique, Paris
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Urinary incontinence among geriatric patients in an acute-care hospital
Authors: H. Sier
Journal: JAMA (1987)

The prevalence, time course, and factors associated with urinary incontinence were examined among 363 patients aged 65 years or older admitted to the acute medical and surgical services of a university hospital. Overall, 35% were incontinent of urine at some time during their hospital stay; incontinence was more common among women and among those older than 75 years. Indwelling catheters were used in 50% of the incontinent patients and 25% of the patients who were otherwise continent while in the hospital. Incontinence was associated with impaired cognitive and physical functioning and with treatment for urinary tract infections. In most of the patients who were incontinent while hospitalized, incontinence was a persistent phenomenon and had been present before hospitalization and was present afterward. Only 5% had "transient" or "nosocomial" incontinence. These data suggest that the acute-care hospital may provide a good opportunity for physicians to identify the often-ignored problem of incontinence, and to then initiate an appropriate diagnostic evaluation of this condition if it persists after hospital discharge. (<i>JAMA</i>1987;257:1767-1771)
P201 No abstract assigned to this number
Authors: Abdullah Al, Mamun Shere, I Du, L O'reilly, A Dwarakanath, V Davison, M Taylor, A Fennerty
Journal: Thorax (2011)

Conclusions 1) Delay within-patient was significantly longer than withinoncology (p<0.0001).2) Over 60% patients visited their GP more than once.3) Delay and stage were unrelated in our study.4) Chest symptoms increased considerably during the pathway to treatment.5) A number of common symptoms were associated with advanced disease.To wheeze, or not to wheeze: is it all asthma?P200
Discussion on Endocrinology.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retrograde aortic dissection occurring during cardiopulmonary bypass. Successful repair and concominant subclavian-to-coronary artery vein bypass
Authors: A. M. Bilgutay
Journal: JAMA (1976)

A retrograde aortic dissection that occurred during cardiopulmonary bypass was successfully repaired. The cause of dissection was related to the jet of retrograde perfusion. The use of subclavian-to-coronary artery vein bypass when the ascending aorta is not suitable for vein anastomosis because of dissection or aneurysms appears to be a satisfactory alternative to aortacoronary bypass. (<i>JAMA</i>236:465-468, 1976)
Abstract P298: Neck Circumference is Associated with Carotid Intimal-media Thickness but Not with Coronary Artery Calcium: Results From the Brazilian Longitudinal Study of Adult Health ELSA-Brasil
Authors: Cristina P Baena, Paulo Lotufo, Itamar Santos, Alessandra Goulart, Marcio S Bittencourt, Bruce B Duncan, Simin Liu, Isabela Benseñor
Journal: Circulation (2016)

Introduction: Neck circumference has been independently associated with cardiovascular risk factors in various populations. Whether neck circumference can be a risk indicator for subclinical atherosclerosis remains uncertain. Hypothesis: Neck circumference can be a marker of local subclinical atherosclerosis in The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Methods: In cross-sectional and sex-specific analyses of 2,266 women (50.6 ±8.4 yrs) and 1,886 men (50.7 ±9.0 yrs) with both cc-IMT and CAC, free from previous coronary heart disease at baseline, we built logistic models using diverse cut-off points for CAC score (0vs&gt;0, &lt;100 vs ≥100, &lt;400 vs ≥400 Agatston units) and cc-IMT ( &lt; 75th percentile vs ≥75 th ; &lt; 90th percentile vs ≥90 th ) as dependent variables, after which adjustments for age and traditional cardiovascular risk factors were made. Results: Mean (standard deviation) neck circumference was 33.6 (±2.4 cm) for women and 38.8 (±2.6 cm) for men. In fully adjusted models including sociodemographic, cardiovascular risk factors and body-mass index (BMI) and waist circumference, for each 1 standard deviation increase in neck circumference we found an odds ratio (OR, 95% CI) for having IMT above the 75th percentile of [1.52, 1.16; 1.99)]for women and [1.66, 1.28; 2.14)] for men, and above the 90th cc-IMT percentile [1.66 (1.19; 2.32)]for men but not for women [1.21 (0.80; 1.82)]. We found no association between neck circumference and CAC using several different cut-off points (p&gt;0.05 for all). Conclusion: Neck circumference was significantly and independently associated with cc-IMT but not with CAC in women and men, indicating a possible effect of perivascular fat tissue on atherosclerosis.
THE EARLY DIAGNOSIS OF CANCER OF THE STOMACH.
Authors: CHAS. D. AARON
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The microenvironment in myelodysplastic syndromes: From concept to therapeutic target
Authors: Marc H.G.P. Raaijmakers
Journal: HemaSphere (2018)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CCBY-NC-ND), which allows third parties to download the abstracts and share them with others as long as they credit the author and the abstract book, but they cannot change the content in any way or use them commercially. http://creativecommons.org/licenses/by-nc-nd/4.0
Budesonide and formoterol inhibit ICAM-1 and VCAM-1 expression of human lung fibroblasts
Authors: F.M Spoelstra, D.S Postma, H Hovenga, J.A Noordhoek, H.F Kauffman
Journal: European Respiratory Journal (2000)

The glucocorticoid budesonide and the long-acting beta2-adrenoceptor agonist formoterol are used in asthma therapy for their anti-inflammatory and bronchodilating effects, respectively. Since expression of adhesion molecules on resident cells in the lung plays an important role in asthmatic inflammatory responses, the effects of these drugs on the cytokine-induced intercellular adhesion molecule-1 (ICAM)-1 and vascular cell adhesion molecule-1 (VCAM)-1 expression of human lung fibroblasts were investigated. Budesonide and formoterol were added in the absence or presence of interleukin (IL)-1beta, tumour necrosis factor-alpha (TNF-alpha), interferon gamma (IFN-gamma) or IL-4 to human lung fibroblasts; ICAM-1 and VCAM-1 expression were measured after 8 h using a cell surface enzyme linked immunosorbent assay (ELISA). It was found that both budesonide and formoterol significantly inhibited (p&lt;0.05) the increased expression of ICAM-1 and VCAM-1 after stimulation with IL-1beta (maximal inhibition (median (25-75% percentiles) 50 (48-52) and 61% (42-69), respectively, with budesonide and 55 (50-73) and 86% (64-94), respectively, with formoterol (10(-7) M)), TNF-alpha (maximal inhibition 49 (46-57) and 57% (44-68), respectively, with budesonide and 44 (40-75) and 62% (52-83) respectively, with formoterol), IFN-gamma (maximal inhibition 64% (41-67) with budesonide and 39% (29-49) with formoterol for ICAM-1) and IL-4 (maximal inhibition 82% (69-92) with budesonide and 43% (33-67) with formoterol for VCAM-1) in a dose-dependent manner. The results show that budesonide, as well as formoterol, in probably clinically relevant concentrations inhibits cytokine-induced adhesion molecule expression on human lung fibroblasts from a concentration of 10(-9) M. This inhibitory effect on resident cells may have implications for the infiltration of inflammatory cells into pulmonary tissue during therapy with these drugs in asthma.
FEBS Letters, Amsterdam
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Juvenile Thyrotoxicosis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacokinetic study of aldoxorubicin in solid tumor patients.
Authors: Monica M. Mita, Ronald B. Natale, Edward M. Wolin, Hillary Dinh, Scott Wieland, Daniel J. Levitt, Alain C. Mita
Journal: Journal of Clinical Oncology (2014)

e13557 Background: Aldoxorubicin (A) is comprised of doxorubicin (D) conjugated to an acid sensitive linker that is covalently attached to serum albumin. We studied the pharmacokinetics (PK) of A to identify albumin-bound D, free D and doxorubicinol (DR) in patients with advanced solid malignancies. Methods: Eligibility criteria: solid tumors with no standard therapy; ECOG PS 0-2; LVEF >45% of predicted normal; ANC>2000/mm3; Hct >25% male, 28% female; platelets >103/mm3. Patients were administered either 230 mg/m2 A (165 mg/m2 D equivalents) or 350 mg/m2 A (260 mg/m2D equivalents) iv over 30 min on Day 1 of each 3 week cycle. Blood samples for PK were taken at administration and at multiple time points up to 72 hours after administration during cycles 1 and 3. Serum and urine concentrations of albumin-bound D, free D, DR and urine D and DR were measured. Results: 18 subjects were entered in the study, 11 received 230 mg/m2 A and 7 received 350 mg/m2 A. 1 SAE, febrile neutropenia, was reported and 2 deaths due to tumor progression occurred. Grades 3&4 AEs included neutropenia, anemia and thrombocytopenia. A minor response (25% decrease, 230 mg/m2) was observed in one patient with small cell lung cancer who had received 3 prior treatments. This patient is ongoing after receiving 20 cycles with no evidence of cardiotoxicity. Other patients have received 8-10 cycles of drug. Similar results were seen for cycle 3. Free D accounted for only 0.3 and 0.4% of total D, and DR less than 0.0007% of total drug. Over 72 h, total urine D was 1.3% and 2.3% of the administered 230 mg/m2 and 350 mg/m2doses, respectively, and total urine DR was 0.001% and 0.003% of the two doses over 72 h. Conclusions: Aldoxorubicin binds rapidly to albumin, has a narrow volume of distribution, a long half-life, is cleared slowly from the circulation, and little D or DR is found in urine, which differs from the published PK for doxorubicin. Clinical trial information: NCT01706835.PK data during cycle 1 for A. Dose Cmax (µg/mL) tmax (hr) t1/2 (hr) AUCt-∞ (h*µg/mL) CLpred (L/h/m2) Vss pred (L/m2) 230 mg/m2 69 0.75 20.5 1,490 0.145 3.78 350 mg/m2 102 1.0 20.0 2,600 0.126 3.41